Purpose: Scintillation dosimetry has promising qualities for ultra-high-dose-rate (UHDR) radiation therapy (RT), but no system has shown compatibility with mean dose rates (DR¯) above 100 Gy/s and doses per pulse (D) exceeding 1.5 Gy typical of UHDR (FLASH)-RT. The aim of this study was to characterize a novel scintillation dosimetry system with the potential of accommodating UHDRs.
Methods And Materials: We undertook a thorough dosimetric characterization of the system on an UHDR electron beamline. The system's response as a function of dose, DR¯, D, and the pulse dose-rate (DR) was investigated, as was the system's dose sensitivity (signal per unit dose) as a function of dose history. The capabilities of the system for time-resolved dosimetric readout were also evaluated.
Results: Within a tolerance of ±3%, the system exhibited dose linearity and was independent of DR¯ and D within the tested ranges of 1.8 to 1341 Gy/s and 0.005 to 7.68 Gy, respectively. A 6% reduction in the signal per unit dose was observed as DR was increased from 8.9e4 to 1.8e6 Gy/s. The dose delivered per integration window of the continuously sampling photodetector had to remain between 0.028 and 11.56 Gy to preserve a stable signal response per unit dose. The system accurately measured D of individual pulses delivered at up to 120 Hz. The day-to-day variation of the signal per unit dose in a reference setup varied by up to ±13% but remained consistent (<±2%) within each treatment day and showed no signal loss as a function of dose history.
Conclusions: With daily calibrations and DR-specific correction factors, the system reliably provides real-time, millisecond-resolved dosimetric measurements of pulsed conventional and UHDR beams from typical electron linacs, marking an important advancement in UHDR dosimetry and offering diverse applications to FLASH-RT and related fields.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2024.11.092 | DOI Listing |
Pediatr Infect Dis J
January 2025
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Background: In Catalonia, infants <6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyze nirsevimab's effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compared them with the catch-up cohort (born from April to September 2023).
Methods: Retrospective cohort study of all infants born between October 1, 2023, and January 21, 2024, according to their immunization with nirsevimab (immunized and nonimmunized).
EClinicalMedicine
August 2024
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background: In an interim analysis of this phase 2 trial, adding the GX-188E vaccine to pembrolizumab resulted in manageable toxicity with antitumor activities in patients with recurrent or advanced cervical cancer. Here, we report the final safety and efficacy results after a long-term follow-up at the study's completion.
Methods: This open-label, single-arm, phase II trial was conducted in nine hospitals in South Korea (ClinicalTrials.
Fish Physiol Biochem
January 2025
Fish Disease Department, Faculty of Veterinary Medicine, Aswan University, Aswan, 81528, Egypt.
Currently, deacetylated chitin (chitosan) nanoparticles (CNPs) are successfully utilized in aquaculture practices. This trial demonstrates the efficacy of CNPs in combating diazinon (DZN) toxicity in African catfish, Clarias gariepinus, via monitoring hepato-renal function, serum immune trait, hormonal function, and hepato-renal antioxidant activity. Four groups were allocated as follows: a control group, a CNPs group (0.
View Article and Find Full Text PDFMod Rheumatol
January 2025
Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
Objectives: This study aimed to describe the characteristics, inflammatory markers as surrogates for disease activity, and treatment of patients with polymyalgia rheumatica (PMR) in Japan.
Methods: This cohort study analysed the data of 373 patients with PMR retrieved from an electronic medical records database in Japan. Patients were classified into quartiles, based on the daily glucocorticoid dose over the initial 90 days of treatment (Q1-Q4).
Surg Endosc
January 2025
Department of General and Gastrointestinal Surgery, Complejo Asistencial Universitario de Salamanca, Paseo de la Transición Española, 37007, Salamanca, Spain.
Background: Different techniques have been proposed to reduce the incidence of the intraoperative bile duct injury during laparoscopic cholecystectomy (LC). Among these, Near-Infrared Fluorescence Cholangiography (NIFC) with Indocyanine Green (ICG) represents a relatively recent addition. At present, there is considerable variation in the protocols for the administration of ICG.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!